Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Mikhail Vnuchkov
Mikhail Vnuchkov

FDA grants Outlook Therapeutics green light for LYTENAVA treatment in neovascular AMD

FDA grants Outlook Therapeutics green light for LYTENAVA treatment in neovascular AMD
Outlook Therapeutics wins FDA nod

Outlook Therapeutics has announced that its drug LYTENAVA has become the first and only FDA-approved ophthalmic formulation of bevacizumab for treating neovascular (wet) age-related macular degeneration (nAMD) in retina practice.

This anti-VEGF therapy aims to address a significant unmet need within ophthalmology and retina care. The approval opens new treatment pathways for patients with wet AMD, with Outlook Therapeutics positioning LYTENAVA as a differentiated solution in a competitive therapeutic landscape.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Asia's largest IPO: How CXMT became China's most valuable company
  • By Mikhail Vnuchkov
  • 32 min ago
Asia's largest IPO: How CXMT became China's most valuable company
Editors' Picks
Global fintech in 2026: Three trends that matter
  • By Pavlo Kot
  • 23 hours ago
Global fintech in 2026: Three trends that matter
Editors' Picks
From Jesus Christ to aliens: Polymarket's most absurd prediction markets
  • By Pavlo Kot
  • Yesterday
From Jesus Christ to aliens: Polymarket's most absurd prediction markets
Editors' Picks
All Editors' Top Picks

Latest Outlook Therapeutics News

Outlook Therapeutics advances new therapies to improve retinal disease care
  • By Andrey Mastykin
  • 12.06.2026
Outlook Therapeutics advances new therapies to improve retinal disease care
Companies
#Outlook Therapeutics
U.S. FDA receives ONS-5010 Biologics License Application from Outlook Therapeutics
  • By Mikhail Vnuchkov
  • 01.06.2026
U.S. FDA receives ONS-5010 Biologics License Application from Outlook Therapeutics
Companies
#Outlook Therapeutics
Outlook Therapeutics prices 5 million direct offering at market under Nasdaq rules
  • By Oleg Tkachenko
  • 28.05.2026
Outlook Therapeutics prices 5 million direct offering at market under Nasdaq rules
Companies
#Outlook Therapeutics
All Outlook Therapeutics News
  • Mikhail Vnuchkov
  • 32 min ago
Asia's largest IPO: How CXMT became China's most valuable company
  • Pavlo Kot
  • 23 hours ago
Global fintech in 2026: Three trends that matter
  • Pavlo Kot
  • Yesterday
From Jesus Christ to aliens: Polymarket's most absurd prediction markets
  • Andrey Mastykin
  • 25.07.2026
Hunting crypto owners: Why criminals have gone offline
  • Eugene Komchuk
  • 24.07.2026
BitMEX is shutting down: Why Trump could not save the exchange
  • Daria Chernytska
  • 3 min ago
James Van Straten: Bitcoin defies historical trend by rising on day 294 of bear market
  • Yaroslav Dmytrenko
  • 24 min ago
Sumit Gupta: CoinDCX enhances SIP product with new token options
  • Hanna Syniavska
  • 39 min ago
Comprehensive crypto services available on Binance, Yi He notes
  • Igor Krasulya
  • 44 min ago
Javier Blas: Kazakh oil export disruption drove $100 crude surge last week
  • Jose Antonio Gastelum
  • 2 hours ago
Holding altcoins only in confirmed bull trends drives returns, Ivan Liljeqvist argues
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.
Top News
  • Ivan Andriyenko
  • 58 min ago
Nvidia considers $250 billion support for OpenAI project
Nvidia considers $250 billion support for OpenAI project
  • Hanna Syniavska
  • 1 hour ago
Brent falls below $90 as Middle East tensions ease
Brent falls below $90 as Middle East tensions ease
  • Eugene Komchuk
  • 2 hours ago
Storj Labs files for bankruptcy
Storj Labs files for bankruptcy
  • Pavlo Kot
  • 23 hours ago
Global fintech in 2026: Three trends that matter
Global fintech in 2026: Three trends that matter
  • Pavlo Kot
  • Yesterday
From Jesus Christ to aliens: Polymarket's most absurd prediction markets
From Jesus Christ to aliens: Polymarket's most absurd prediction markets
Live News
  • Mykhailo Ihnatenko
  • Now
Mixed quarterly results keep BT Group shares in consolidation
  • Mykhailo Ihnatenko
  • Now
Rolls-Royce shares near record high ahead of half-year results
  • Mykhailo Ihnatenko
  • Now
Solana price follows crypto rebound but volume remains weak
  • Mykhailo Ihnatenko
  • Now
Ethereum price eyes $2,000 as U.S.-Iran tensions ease
  • Anton Kharitonov
  • Now
Microsoft steadies after selloff as AI fundamentals remain intact
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR